SCOLR Pharma, Inc. First Quarter 2011 Financial Results

Wednesday, May 11, 2011 General News
Email Print This Page Comment
Font : A-A+

SCOLR Pharma, Inc.

CONDENSED UNAUDITED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts and number of shares)

Three months ended

March 31,

2011

2010

(Restated)

Revenues

Licensing fees

$

$

25

Royalty income

66

141

Research and development

118

Total revenues

184

166

Operating expenses

Marketing and selling

125

59

Research and development

647

340

General and administrative

740

601

Total operating expenses

1,512

1,000

Loss from operations

(1,328)

(834)

Other income (expense)

Interest income

1

1

Unrealized gain (loss) on fair value of warrant

105

(218)

Total other income (expense)

106

(217)

Net loss

$

(1,222)

$

(1,051)

Net loss per share, basic and diluted

$

(0.02)

$

(0.02)

Shares used in computing basic and diluted net loss per share

49,816,073

43,140,968



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook